Trial Profile
A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jan 2024
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Taragarestrant (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors InventisBio
- 04 Jan 2024 Status changed from active, no longer recruiting to completed.
- 04 Apr 2023 Planned End Date changed from 1 Jul 2023 to 22 Sep 2023.
- 05 May 2022 Planned End Date changed from 1 Dec 2022 to 1 Jul 2023.